BLA 761344 · Amgen INC
Imdelltra
Tarlatamab-Dlle · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 16, 2024: To treat extensive stage small cell lung cancer
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
May 16, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
40
8 Phase 3, 20 recruiting
FAERS reports
10
10 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA. Initiate IMDELLTRA using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.5) and Warnings and Precautions (5.1) ] . Neurologic toxicity and immune effector cell-associated neurotoxicity syndrome (ICANS), including life-threatening or fatal reactions, can occur in patients receiving IMDELLTRA. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment and treat promptly. Withhold IMDELLTRA until ICANS resolves or permanently discontinue based on severity [see Dosage...
What it is approved for
From the label in effect Sep 11, 2026.
IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum - based chemotherapy. ( 1 )
Mechanism: Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 19, 2025 Supplement 1 · Efficacy · priority review OrphanLabelLetter
- May 16, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- IMDELLTRA · TARLATAMAB-DLLE 1MG · INJECTABLE, INJECTION · Prescription
- IMDELLTRA · TARLATAMAB-DLLE 10MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tarlatamab" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT06551142 · 845 participants (planned) · Start Sep 30, 2024 · Primary completion Oct 16, 2028
Drug: Ris-Rez; Cisplatin and 8 more · For: Neoplasms
Sites: Stanford, California; Denver, Colorado; New Haven, Connecticut · 67 sites in all
- Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06211036 · 563 participants · Start Jun 5, 2024 · Primary completion Apr 2, 2030
Drug: Tarlatamab; Durvalumab · For: Extensive-Stage Small-Cell Lung Cancer; Small-Cell Lung Cancer
Sites: Mobile, Alabama; Los Angeles, California; New Haven, Connecticut · 219 sites in all
PfizerPfizer (PFE)
NCT07226999 · 550 participants (planned) · Start Dec 9, 2025 · Primary completion Jun 14, 2030
Drug: PF-08634404; Tarlatamab and 2 more · For: Small Cell Lung Cancer (SCLC)
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 85 sites in all
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT05740566 · 509 participants · Start May 31, 2023 · Primary completion Jan 29, 2025
Drug: Tarlatamab; Lurbinectedin and 2 more · For: Small Cell Lung Cancer (SCLC)
Sites: Mobile, Alabama; Anchorage, Alaska; Little Rock, Arkansas · 223 sites in all
- Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerPivotal-lookingNot yet recruiting
PrECOG, LLC.Academic, hospital or other
NCT07637513 · 430 participants (planned) · Start Jan 2027 · Primary completion Nov 2037
Drug: Tarlatamab; Durvalumab · For: Limited Stage Small-Cell Lung Cancer
- Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06117774 · 404 participants · Start Feb 20, 2024 · Primary completion Apr 20, 2030
Drug: Tarlatamab; Placebo · For: Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer
Sites: Los Angeles, California; Santa Monica, California; New Haven, Connecticut · 204 sites in all
- Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07778316 · 400 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 24, 2027
Drug: Tarlatamab · For: Small Cell Lung Cancer
Sites: Orlando, Florida; Grand Rapids, Michigan; Omaha, Nebraska · 9 sites in all
AmgenAmgen (AMGN)
NCT07037758 · 380 participants (planned) · Start Sep 16, 2025 · Primary completion Mar 18, 2028
Drug: Tarlatamab; AB248 · For: Extensive Stage Small Cell Lung Cancer
Sites: Gilbert, Arizona; Los Angeles, California; Tampa, Florida · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome4
- immune effector cell-associated neurotoxicity syndrome4
- acute respiratory failure2
- dyspnoea2
- fatigue2
- pain2
- adverse event1
- asthenia1
- atrial fibrillation1
- cardio-respiratory arrest1
- cardiomyopathy1
- cardiovascular disorder1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imdelltra (Tarlatamab-Dlle)
2024 spending
$483K
Beneficiaries
n/a
26 claims
Per beneficiary
n/a
$10,867.13 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $483,436 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios G, Sun L, Cho BC, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ, Cho BC, Felip E, et al. · N Engl J Med 2023 · Clinical Trial, Phase II
- Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
Paulson KG, Lau SCM, Ahn MJ, et al. · Lancet Oncol 2025 · Multicenter Study, Clinical Trial, Phase I
- Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L, Champiat S, Lai WV, et al. · J Clin Oncol 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn MJ, Cho BC, Felip E, et al. · Future Oncol 2024 · Clinical Trial, Phase III, Multicenter Study
- Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, et al. · J Clin Oncol 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.